Ubs Oconnor LLC Ideaya Biosciences, Inc. Transaction History

Ubs Oconnor LLC

$1.44 Billion
Q1 2025

A detailed history of Ubs Oconnor LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 69,474 shares of IDYA stock, worth $1.36 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

69,474

Holding current value

$1.36 Million

% of portfolio

0.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$16.38 - $26.0 $53,103 - $84,292	-3,242 Reduced 4.46%	69,474 $1.14 Million
Q4 2024 Feb 14, 2025	BUY	$24.79 - $31.98 $597,736 - $771,101	24,112 Added 49.61%	72,716 $1.87 Million
Q3 2024 Nov 14, 2024	SELL	$30.37 - $43.05 $347,615 - $492,750	-11,446 Reduced 19.06%	48,604 $1.54 Million
Q2 2024 Aug 14, 2024	BUY	$34.37 - $43.46 $275,131 - $347,897	8,005 Added 15.38%	60,050 $2.11 Million
Q1 2024 May 15, 2024	SELL	$34.2 - $47.13 $770,526 - $1.06 Million	-22,530 Reduced 30.21%	52,045 $2.28 Million
Q4 2023 Feb 14, 2024	SELL	$24.59 - $35.83 $1.27 Million - $1.85 Million	-51,574 Reduced 40.88%	74,575 $2.65 Million
Q3 2023 Nov 14, 2023	SELL	$21.07 - $29.77 $316,050 - $446,550	-15,000 Reduced 10.63%	126,149 $3.4 Million
Q2 2023 Aug 14, 2023	BUY	$13.33 - $25.53 $1.88 Million - $3.6 Million	141,149 New	141,149 $3.32 Billion
Q1 2023 May 15, 2023	BUY	$13.49 - $18.72 $315,382 - $437,654	23,379 Added 20.23%	138,949 $1.91 Million
Q4 2022 Feb 14, 2023	BUY	$14.47 - $18.17 $513,077 - $644,271	35,458 Added 44.26%	115,570 $0
Q3 2022 Nov 14, 2022	BUY	$9.24 - $15.79 $740,234 - $1.26 Million	80,112 New	80,112 $1.2 Billion

Others Institutions Holding IDYA

# of Institutions

212

Shares Held

80.3M

Call Options Held

80.3K

Put Options Held

30.5K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $940M
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account